Predictors of response to fesoterodine in patients with an overactive bladder

  • Hyeon Woo Kim
  • Jeong Zoo Lee
  • Dong Gil Shin
Original Article


An analysis has been conducted of the predictors of the fesoterodine treatment response for female patients with overactive bladder (OAB) syndrome. Eighty-seven women diagnosed with OAB and who had undergone 12 weeks of treatment with fesoterodine (4 mg/day) were involved. Prior to treatment, the patients were evaluated through their medical history, physical examinations, urine analysis, urine cultures, voiding diaries and urodynamic studies. The voiding diaries and personal interviews concerning urinary symptoms were analyzed 12 weeks after treatment. Seventy-nine (82.3%) women experienced improvement of OAB symptoms (Improvement group), and for seventeen (17.7%) women the symptoms remained unchanged or worsened (Persistence group) after treatment. In the urodynamic studies, detrusor overactivity was noted in 37 (46.8%) patients of the improvement group and 3 (17.6%) of the persistence group. The number of patients who showed detrusor overactivity in urodynamic studies before the treatment was significantly larger in the improvement group. Maximum detrusor pressure and detrusor pressure at maximum flow were higher in the persistence group but not to statistically significant levels. In pre-treatment voiding diaries, the number of urgencies per day was significantly larger in the improvement group. The efficacy of fesoterodine treatment for female OAB problems was found to be be associated with the frequency of urgency and detrusor overactivity. Thus, both voiding diaries and urgency/detrusor symptom records may aid in predicting the efficacy of fesoterodine treatment.


Fesoterodine Overactive bladder Women 



We express our deep appreciation to Dr. Jack M. Harrowfield who has kindly improved the English of our manuscript.


  1. 1.
    Sand, P.K., Morrow, J.D., Bavendam, T., Creanga, D.L., Nitti, V.W.: Efficacy and tolerability of fesoterodine in women with overactive bladder. Int. Urogynecol. J. 20, 827–835 (2009)CrossRefGoogle Scholar
  2. 2.
    Chapple, C., Kerrebroeck, P.V., Tubaro, A., Haag-Molkenteller, C., Forst, H.-T., Massow, U., Wange, J., Brodsky, M.: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Europ. Urol. 52, 1204–1212 (2007)CrossRefGoogle Scholar
  3. 3.
    Nitti, V.W., Dmochowski, R., Sand, P.K., Forst, H.-T., Haag-Molkenteller, C., Massow, U., Wang, J., Brodsky, M., Bavendam, T.: Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J. Urol. 178, 2488–2494 (2007)CrossRefGoogle Scholar
  4. 4.
    Kraus, S.R., Ruiz-Cerdá, J.L., Martire, D., Wang, J.T., Wagg, A.S.: Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 76, 1350–1357 (2010)CrossRefGoogle Scholar
  5. 5.
    Cardozo, L., Khullar, V., El-Tahtawy, A., Guan, Z., Malhotra, B., Staskin, D.: Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. BMC Urol. 10, 14 (2010)CrossRefGoogle Scholar
  6. 6.
    Ellsworth, P., Berriman, S.J., Brodsky, M.: Fesoterodine: a new agent for treating overactive bladder. Amer. J. Managed Care. 15, 4 (2009)Google Scholar
  7. 7.
    Herschorn Sender, J., Jones, S., Oelke, M., MacDiarmid, S., Wang, J.T., Guan, Z.: Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology. 75, 1149–1155 (2010)CrossRefGoogle Scholar
  8. 8.
    Meek, P.D., Evang, S.D., Tadrous, M., Roux-Lirange, D., Triller, D.M., Gumustop, B.: Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig. Dis. Sci. 56, 7–18 (2011)CrossRefGoogle Scholar
  9. 9.
    Wyndaele, J.-J., Goldfischer, E.R., Morrow, J.D., Gong, J., Tseng, L.-J., Guan, Z., Choo, M.-S.: Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int. J. Clin. Pract. 63, 560–567 (2009)CrossRefGoogle Scholar
  10. 10.
    Ellsworth, P.: Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag 5, 869–876 (2009)CrossRefGoogle Scholar
  11. 11.
    Van Kerrebroeck, P.E.V., Heesakkers, J., Berriman, S., Aiyer, L.P., Carlsson, M., Guan, Z.: Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int. J. Clin. Pract. 64, 584–593 (2010)CrossRefGoogle Scholar
  12. 12.
    Malhotra, B.K., Crownover, P.H., La Badie, R., Glue, P., MacDiarmid, S.A.: The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. Eur. J. Clin. Pharmacol. 66, 171–176 (2010)CrossRefGoogle Scholar
  13. 13.
    Chapple, C.R., Van Kerrebroeck, P.E., Jünemann, K.-P., Wang, J.T., Brodsky, M.: Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 102, 1128–1132 (2008)CrossRefGoogle Scholar
  14. 14.
    Goldman, H.B., Morrow, J.D., Gong, J., Tseng, L.-J., Schneider, T.: Early onset of fesoterodine efficacy in subjects with overactive bladder. BJU Int. 107, 598–602 (2010)CrossRefGoogle Scholar
  15. 15.
    Herschorn, S., Swift, S., Guan, Z., Carlsson, M., Morrow, J.D., Brodsky, M., Gong, J.: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 105, 58–66 (2009)CrossRefGoogle Scholar
  16. 16.
    Acquadro, C., Kopp, Z., Coyne, K.S., Corcos, J., Tubaro, A., Choo, M.S.: Translating overactive bladder questionnaires in 14 languages. Urology. 67, 536–540 (2006)CrossRefGoogle Scholar
  17. 17.
    Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., Wein, A.: The standardization of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol. Urodyn. 21, 167–178 (2002)CrossRefGoogle Scholar
  18. 18.
    Abrams, P., Blaivas, J.G., Stanton, S.L.: The standardization of terminology of low urinary tract function recommended by the International Continence Society. Int. Urogynecol. J. 1, 45–58 (1990)CrossRefGoogle Scholar
  19. 19.
    Milsom, I., Abrams, P., Cardozo, L., Roberts, R.G., Thuroff, J., Wein, A.J.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87, 760–766 (2001)CrossRefGoogle Scholar
  20. 20.
    Kelleher, C.J., Reese, P.R., Pleil, A.M., Okano, G.J.: Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am. J. Manag. Care 8, S608–S615 (2002)Google Scholar
  21. 21.
    Liberman, J.N., Hunt, T.L., Stewart, W.F.: Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology 57, 1044–1050 (2001)CrossRefGoogle Scholar
  22. 22.
    Coyne, K., Revicki, D., Hunt, T.: Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual. Life Res. 11, 563–574 (2002)CrossRefGoogle Scholar
  23. 23.
    Kim, U.H., Kim, Y.H., Kim, M.E.: The prevalence and quality of life of overactive bladder and urinary incontinence in young women. Korean J. Urol. 45, 543–550 (2004)Google Scholar
  24. 24.
    Abrams, P., Wein, A.J.: Introduction: overactive bladder and its treatments. Urology. 55, 1–27 (2000)CrossRefGoogle Scholar
  25. 25.
    Milsom, I., Stewart, W., Thuroff, J.: The prevalence of overactive bladder. Amer. J. Manag. Care. S565–S573 (2000)Google Scholar
  26. 26.
    Stewart, A.L., Hays, R.D., Ware Jr., J.E.: The MOS short form general health survey. Reliability and validity in a patient population. Med. Care 26, 724–735 (1998)CrossRefGoogle Scholar
  27. 27.
    Elving, L.B., Foldspang, A., Lam, G.W., Mommsen, S.: Descriptive epidemiology of urinary incontinence in 3, 100 women age 30–59. Scand. J. Urol. Nephrol. Suppl. 125, 37–43 (1989)Google Scholar
  28. 28.
    Goepel, M., Hoffmann, J.A., Piro, M., Rubben, H., Michel, M.C.: Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur. Urol. 41, 234–239 (2002)CrossRefGoogle Scholar
  29. 29.
    Lapitan, M.C., Chye, P.L.: The epidemiology of overactive bladder among females in Asia: a questionnaire survey. Int. Urogynecol. J. Pelvic. Floor Dysfunct 12, 226–231 (2001)CrossRefGoogle Scholar
  30. 30.
    Jackson, S.: The patient with an overactive bladder symptoms and quality of life issues. Urology. 50(6A Suppl), 18–22 (1997)CrossRefGoogle Scholar
  31. 31.
    Komaroff, A.L., Fagioli, L.R., Doolittle, T.H.: Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am. J. Med. 101, 281–290 (1996)CrossRefGoogle Scholar
  32. 32.
    Braverman, A.S., Ruggieri, M.R.Sr.: Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Amer. J. Physiol. Regul. Integr. Comp. Physiol. 285, R701–R708 (2003)Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Hyeon Woo Kim
    • 1
  • Jeong Zoo Lee
    • 1
  • Dong Gil Shin
    • 1
  1. 1.Department of UrologyPusan National University School of MedicineSeo-Ku, BusanKorea

Personalised recommendations